1-6 of 6
Connie Lee Batlevi, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

Edith Tama Robin, MD, Esther Drill, DrPH, Connie Lee Batlevi, MDPhD, Philip Caron, MD PhD, Lorenzo Falchi, MD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Andrew M. Intlekofer, MD PhD, Erel Joffe, MD MSc, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Colette Owens, MD, Maria Lia Palomba, MD, Ildefonso Rodriguez-Rivera, MD, David J. Straus, MD, Santosha Vardhana, MD PhD, Gottfried R. von Keudell, MD PhD, Andrew D Zelenetz, MD PhD, Craig H. Moskowitz, MD, Alison J. Moskowitz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-136489
Published: 2020
Journal Articles

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Anita Kumar, MD, Jason Westin, MD, Stephen J Schuster, MD, Grzegorz S. Nowakowski, MD, Izidore S. Lossos, MD, Connie Lee Batlevi, MDPhD, Philip Caron, MD PhD, Pamela Drullinsky, MD, John Gerecitano, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Allison P. Jacob, Erel Joffe, MD MSc, Ashlee Joseph, Gottfried R. von Keudell, MD PhD, Leana Laraque, BA, Oscar B Lahoud, MD, Matthew J Matasar, MD, Craig H. Moskowitz, MD, Chelsea D Mullins, BS, Ariela Noy, MD, Colette Owens, MD, Maria Lia Palomba, Carol S. Portlock, MD, Ildefonso Rodriguez-Rivera, MD, Gilles Salles, MDPhD, Venkatraman Seshan, PhD, David J. Straus, MD, Shreya Vemuri, Anas Younes, Andrew D Zelenetz, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-138889
Published: 2020
Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Gilles Salles, MD PhD, Hervé Tilly, MD, Aristeidis Chaidos, MD PhD, Pam McKay, MD, Tycel J. Phillips, MD, Sarit E Assouline, MD MSc, Connie Lee Batlevi, MDPhD, Philip Campbell, MBBS, Vincent Ribrag, MD, Gandhi Laurent Damaj, MD PhD, Michael Dickinson, DMed Sci, Wojciech Jurczak, MD PhD, Maciej Kaźmierczak, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, John A. Radford, MD FMedSci, Anna Schmitt, MD, Jennifer Whalen, DHS, Anthony Hamlett, PhD, Beth Kamp, PharmD, Deyaa Adib, MD, Franck Morschhauser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-137245
Published: 2020
Journal Articles

Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas

Brandon S. Imber, MD MA, Miguel-Angel Perales, MD, Jessica Flynn, BS, Josel D Ruiz, MPH, Sean Devlin, PhD, Ana Alarcon Tomas, MD, Carla Hajj, MD, Connie Lee Batlevi, MDPhD, Parastoo B. Dahi, MD, Richard J Lin, MDPhD, Jae H. Park, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Sergio A. Giralt, MD, Craig S. Sauter, MD, M. Lia Palomba, MD, Joachim Yahalom, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-140991
Published: 2020
Journal Articles

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

Zachary D. Epstein-Peterson, MD, Connie Lee Batlevi, MDPhD, Philip Caron, MD PhD, Ahmet Dogan, MD PhD, Pamela Drullinsky, MD, John Gerecitano, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Caleb Ho, MD, Allison P. Jacob, Leana Laraque, BA, Matthew J Matasar, MD, Alison J. Moskowitz, MD, Craig H. Moskowitz, MD, Chelsea D Mullins, BS, Colette Owens, MD, Gilles Salles, Heiko Schöder, MD, David J. Straus, MD, Anas Younes, Andrew D Zelenetz, MD PhD, Anita Kumar, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136565
Published: 2020
Journal Articles

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Gunjan Shah, MD, Heiko Schöder, MD, Nivetha Ganesan, MPH, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Samia Sohail, BA, Alayna Santarosa, Lauren Pomerantz, BS, Christine Jarjies, MS, Natasha Galasso, BA, Rachel Neuman, Anita Kumar, MD, Oscar B Lahoud, MD, Connie Lee Batlevi, MDPhD, Paul A. Hamlin, MD, David J. Straus, MD, Ildefonso Rodriguez-Rivera, MD, Colette Owens, MD, Philip Caron, MD PhD, Andrew M. Intlekofer, MD PhD, Audrey Hamilton, MD, Steven M. Horwitz, MD, Lorenzo Falchi, MD, Erel Joffe, MD MSc, Maria Lia Palomba, Ariela Noy, MD, Matthew J Matasar, MD, Georgios Pongas, MD, Santosha Vardhana, MD PhD, Gottfried R. von Keudell, MD PhD, Joachim Yahalom, MD, Andrew D Zelenetz, MD PhD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-138434
Published: 2020